Positive clinical results of cisplatin liposome in the treatment of breast cancer

2023-11-04 19:11:18

February 01, 2018 Source: Sina Pharmaceutical

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

On January 31, Oncology Venture, a subsidiary of the Medical Prognosis Institute (MPI) in Denmark, announced the second phase of the clinical trial of the drug LiPlaCis for the treatment of refractory metastatic breast cancer (in the clinical phase 1/2 study). Interim report.

LiPlaCis is a cisplatin liposome-targeted formulation with 7 clinically remission responses in 10 evaluable patients, whereas traditional cisplatin-treated metastatic breast cancer reported only 10% in previous trials. Efficient. Among the one-third of patients identified by DRP, they were most sensitive to treatment, and all five patients received clinical benefit. In addition, 3 patients who received multiple treatments received longer and better clinical remission than all previous treatments (including hormonal therapy and combination therapy).

Patients enrolled in this clinical phase 1/2 trial were assisted by DRP, a companion diagnostic tool developed by MPI, which would recruit patients who were most likely to respond to treatment.

The Phase 2 trial of this clinical study is expected to recruit 20 evaluable patients with the highest likelihood of response to treatment. The study is progressing as planned, and the last patient is expected to complete the enrollment by the end of the first quarter of 2018.

Dr. Steen Knudsen, founder and chief scientific officer of MPI, said: "In this prospective study, DRP can identify patients with and without response, and is statistically significant."

Dr. Bent Ejlertsen, Chairman of the Scientific Medical Committee of the Danish Breast Cancer Cooperation Group and the University of Copenhagen, Dr. Bent Ejlertsen, said: "All oncologists want to choose the right anticancer therapy for their patients, and avoid treatment that is unfavourable to patients. There is an urgent need for a detection technique similar to Oncology Ventures' DRP, which is promising in identifying patients who are effective in treating anticancer drugs."

So far, a total of 17 patients in the second phase of the clinical trial have been enrolled, and 10 of them have been followed for a long enough period to assess efficacy. Of these patients, a total of 7 patients achieved clinical outcomes, 2 of whom had partial remission (PR) and 5 patients had stable disease (SD). Three patients had progressive disease (PD), and three patients were unable to assess efficacy (2 patients had died earlier - have been determined to be unrelated to drug therapy, and another failed to enroll).

The trial data of DRP screening and exclusion of patients who had previously received platinum treatment were:

1. Of the 5 patients who had received an average of 7 treatments before, all had clinical benefit (partial response + stable disease) and lasted an average of 25 weeks. The average benefit time of their recent treatment was only 14 weeks.

2. Compared with all previous treatments, 3 of 5 patients (2 patients with partial response and +1 stable disease) had better efficacy or longer duration of treatment. (Sina Pharmaceutical Compilation / David)

Article Reference Source: MPI'S SPINOUT ONCOLOGY VENTURE ANNOUNCES POSITIVE INTERIM RESULTS FROM A PHASE 1/2 DRP GUIDED STUDY OF LIPLACIS IN HEAVILY PRETREATED BREAST CANCER PATIENTS

Greenhouse Wet Pad For Cooling System

"Wet curtain - fan" of the vertical ventilation cooling combination is the most economical and effective measures to cool the greenhouse in summer.
Years from the application of a real show, even in the heat of the day reported, the rational design and installation of a fan of wet curtain cooling system can still control the greenhouse temperature at 30 Â°C, in order to heat the greenhouse to reduce the adverse effects minimum. In the summer, your production needs Jienuo wet curtain to help.

Greenhouse Wet Pad For Cooling System,Greenhouse Wet Curtain,Greenhouse Cooling Pad,Greenhouse Cooling Paper

JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.engreenhouse.com